Mainstay Capital Management’s AstraZeneca AZN Stock Holding History

Mainstay Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,652	Closed	-$400K	–	109
2020 Q3	$400K	Sell	3,652 -60	-2%	-$6.67K	0.1%	81
2020 Q2	$392K	Buy	3,712 +285	+8%	+$29.4K	0.11%	80
2020 Q1	$305K	Buy	3,427 +512	+18%	+$48.2K	0.1%	75
2019 Q4	$291K	Sell	2,915 -915	-24%	-$86.1K	0.07%	89
2019 Q3	$341K	Hold	3,830	–	–	0.19%	71
2019 Q2	$316K	Buy	+3,830	New	+$300K	0.17%	78
2018 Q4	–	Sell	-110	Closed	-$9K	–	111
2018 Q3	$9K	Hold	110	–	–	0.01%	343
2018 Q2	$8K	Buy	110 +1	+0.9%	+$72	0.01%	335
2018 Q1	$7K	Sell	109 -1	-0.9%	-$69	0.01%	252
2017 Q4	$8K	Buy	+110	New	+$7.42K	0.01%	272

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mainstay Capital Management's AZN Position: Q4 2020 in Review

Mainstay Capital Management sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 3,652 shares — an estimated $400K sold.

Mainstay Capital Management first reported a position in AZN in Q4 2017 and held it in 10 quarters. The position peaked at $400K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

Mainstay Capital Management reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
Mainstay Capital Management sold 3,652 AstraZeneca shares in Q4 2020, an estimated $400K.
Mainstay Capital Management first reported a position in AstraZeneca in Q4 2017 and held it in 10 quarters.
Mainstay Capital Management's AstraZeneca position peaked at $400K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Mainstay Capital Management's 13F filing for Q4 2020, filed 4 Mar 2021.